- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Enrollment change: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Oct 13, 2023
P3, N=97, Active, not recruiting,
Recruiting --> Active, not recruiting | N=200 --> 97
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Enrollment change: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - May 3, 2023
P3, N=140, Active, not recruiting,
No abstract available Recruiting --> Active, not recruiting | N=200 --> 140
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Dec 7, 2022
P2, N=2630, Recruiting,
Recruiting --> Active, not recruiting | N=200 --> 140 Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Nov 14, 2022
P3, N=200, Recruiting,
Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jul 2026 Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Nov 14, 2022
P3, N=200, Recruiting,
Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024 Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Nov 14, 2022
P3, N=200, Recruiting,
Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024 Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2026 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Dec 2, 2021
P2, N=2630, Recruiting,
Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2026 --> Dec 2024 Trial completion date: Feb 2026 --> Jun 2026
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Nov 4, 2021
P3, N=200, Recruiting,
Trial completion date: Feb 2026 --> Jun 2026 Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Nov 4, 2021
P3, N=200, Recruiting,
Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025 Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Nov 4, 2021
P3, N=200, Recruiting,
Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025 Trial completion date: Dec 2027 --> Sep 2026 | Trial primary completion date: Dec 2026 --> Sep 2026
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Clinical, Journal: Prolonged-release buprenorphine formulations: Perspectives for clinical practice. (Pubmed Central) - Sep 19, 2021
Buvidal®/Brixadi® is a one-week- or one-month-long depot formulation with multiple dosages, which can be used in initiation or in switched from sublingual formulations. While opioid users report some concerns with a risk of coercive use of long-acting forms of buprenorphine, both users and professionals deem that these new specialties could be particularly appreciated in stabilized patients bothered with the daily intake of the treatments, or specific situations at risk of treatment dropout (e.g., following hospital discharge or prison release).
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment open, Enrollment change: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Jul 21, 2021
P3, N=200, Recruiting,
While opioid users report some concerns with a risk of coercive use of long-acting forms of buprenorphine, both users and professionals deem that these new specialties could be particularly appreciated in stabilized patients bothered with the daily intake of the treatments, or specific situations at risk of treatment dropout (e.g., following hospital discharge or prison release). Not yet recruiting --> Recruiting | N=300 --> 200
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment change: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Jul 16, 2021
P3, N=200, Recruiting,
Not yet recruiting --> Recruiting | N=300 --> 200 N=300 --> 200
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Phase classification, Enrollment change: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Mar 15, 2021
P2, N=2630, Not yet recruiting,
Not yet recruiting --> Recruiting Phase classification: P4 --> P2 | N=1630 --> 2630
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Feb 10, 2021
P4, N=1630, Not yet recruiting,
Phase classification: P4 --> P2 | N=1630 --> 2630 Trial completion date: Jul 2025 --> Dec 2025 | Initiation date: Oct 2020 --> Apr 2021 | Trial primary completion date: Jul 2025 --> Dec 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Dec 19, 2020
P3, N=300, Recruiting,
Trial completion date: Jul 2025 --> Dec 2025 | Initiation date: Oct 2020 --> Apr 2021 | Trial primary completion date: Jul 2025 --> Dec 2025 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Dec 19, 2020
P3, N=300, Recruiting,
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Dec 19, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment open: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Jul 8, 2020
P3, N=300, Recruiting,
Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026 Not yet recruiting --> Recruiting
- |||||||||| Sublocade (buprenorphine once-monthly depot) / Indivior
Clinical, Journal: Prolonged-release buprenorphine formulations: Perspectives for clinical practice (Pubmed Central) - Jun 6, 2020
Buvidal®/Brixadi® is a one-week- or one-month-long depot formulation with multiple dosages, which can be used in initiation or in switched from sublingual formulations. While opioid users report some concerns with a risk of coercive use of long-acting forms of buprenorphine, both users and professionals deem that these new specialties could be particularly appreciated in stabilized patients bothered with the daily intake of the treatments, or specific situations at risk of treatment dropout (e.g., following hospital discharge or prison release).
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Jun 5, 2020
P3, N=300, Not yet recruiting,
While opioid users report some concerns with a risk of coercive use of long-acting forms of buprenorphine, both users and professionals deem that these new specialties could be particularly appreciated in stabilized patients bothered with the daily intake of the treatments, or specific situations at risk of treatment dropout (e.g., following hospital discharge or prison release). Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Jun 5, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023 Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Jun 5, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023 Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion, Enrollment change: Phase II Pharmacokinetics Study of CAM2038 (clinicaltrials.gov) - Apr 30, 2020
P2, N=66, Completed,
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024 Active, not recruiting --> Completed | N=50 --> 66
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion, Enrollment change: Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Feb 7, 2020
P3, N=676, Completed,
Active, not recruiting --> Completed | N=50 --> 66 Active, not recruiting --> Completed | N=340 --> 676
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Feb 6, 2020
P3, N=300, Not yet recruiting,
Active, not recruiting --> Completed | N=340 --> 676 Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Feb 6, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023 Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Oct 2020 --> May 2021 | Trial primary completion date: Jan 2024 --> Aug 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Feb 6, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Oct 2020 --> May 2021 | Trial primary completion date: Jan 2024 --> Aug 2024 Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial initiation date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Sep 24, 2019
P3, N=300, Not yet recruiting,
Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023 Initiation date: Aug 2019 --> Nov 2019
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Trial completion date, Trial primary completion date: Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Jul 18, 2018
P3, N=340, Active, not recruiting,
Phase classification: P=N/A --> P3 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jan 2019 | Trial primary completion date: Dec 2017 --> May 2018
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion: Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=228, Completed,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jan 2019 | Trial primary completion date: Dec 2017 --> May 2018 Active, not recruiting --> Completed
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion: Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence (clinicaltrials.gov) - Nov 21, 2016
P3, N=429, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed: Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=228, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial initiation date, Trial primary completion date: Phase II Pharmacokinetics Study of CAM2038 (clinicaltrials.gov) - Oct 11, 2016
P2, N=50, Active, not recruiting,
Recruiting --> Active, not recruiting Initiation date: Feb 2016 --> Feb 2015 | Trial primary completion date: Sep 2016 --> Mar 2017
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed: Phase II Pharmacokinetics Study of CAM2038 (clinicaltrials.gov) - Jul 20, 2016
P2, N=50, Active, not recruiting,
Initiation date: Feb 2016 --> Feb 2015 | Trial primary completion date: Sep 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus
Trial completion: A Multiple Dose Opioid Challenge Study (clinicaltrials.gov) - May 11, 2016
P2, N=47, Completed,
N=160 --> 228 Enrolling by invitation --> Completed
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Enrollment change: Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence (clinicaltrials.gov) - Apr 12, 2016
P3, N=433, Active, not recruiting,
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting | N=252 --> 433
|
